We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Srilakshmi
Gollapothu
Srilakshmi.Gollapothu@ppdi.com
Tom
Buckley
tom.buckley2@nhs.net
Carolina
Abreu
carolina.abreu@ouh.nhs.uk
Joseph
Terry
joseph.terry@ouh.nhs.uk
Disorders of sclera, cornea, iris and ciliary body
This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.
Ocular inflammatory disease is a broad term for a diverse group of infectious and immune mediated diseases which lead to inflammation in various parts of the eye. Ocular inflammation affects about 1 in 5000 individuals and is the third leading cause of blindness in the western world. Within this umbrella, uveitis is an important and common subtype of ocular inflammation. The term uveitis refers to inflammation of the uveal tract, which is comprised of the iris, ciliary body and choroid. Uveitis may be infectious or non-infectious, and is usually classified anatomically into anterior, intermediate and posterior uveitis. Of these anterior uveitis is the most common, with a prevalence of nearly 50 per 100,000 people, and has considerable morbidity, causing eye pain and reduction in vision. It is common in working age people, and therefore has marked economic impact. Anterior uveitis may also be associated with a group of autoimmune diseases called the seronegative spondyloarthropathies, which includes ankylosing spondylitis.
We aim to utilise tissue and eye fluid specimens from patients with different forms of uveitis and ocular inflammatory disease to identify the specific cell types and proteins that are present during active inflammation. This would be done using various laboratory techniques, including flow cytometry, protein analysis, and single-cell RNA sequencing. RNA is the messenger genetic code cells use to make protein. Using this cutting-edge technique it is possible to identify types of cells, that may only be present in very small numbers, and take a snapshot of their activity during inflammation. Using a combination of these techniques we hope to identify underlying causes of inflammation, which are not always known, as well as potential molecular targets for new therapies.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
Patients: Aged below 18 years Unable to give informed consent. Controls: Aged below 18 years Unable to give informed consent. Any history of uveitis or ocular cicatrial pemphigoid
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Joseph
Terry
joseph.terry@ouh.nhs.uk
Srilakshmi
Gollapothu
Srilakshmi.Gollapothu@ppdi.com
Tom
Buckley
tom.buckley2@nhs.net
Carolina
Abreu
carolina.abreu@ouh.nhs.uk
The study is sponsored by University of Oxford and funded by Medical Research Council (MRC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 53160
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
